Position history for Capital Research Global Investors's holdings in ALNYLAM PHARMACEUTICALS INC
Capital Research Global Investors holds 9.5M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), worth $3.1B as of 2026-Q1. The position was increased (+39.7% shares). ALNY represents 0.5% of Capital Research Global Investors's portfolio.
Current Value
$3.1B
Current Shares
9.5M
Total Value Change
+$2.3B
Total Shares Change
+6.2M
Other major holders of ALNY: UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Increased |
| 9.5M |
+39.7% |
| $3.1B |
| 0.5% |
| $318.65 |
51 |
| 2025-Q4 | Decreased | 6.8M | -6.1% | $2.7B | 0.5% | $397.25 | 0 |
| 2025-Q3 | Increased | 7.2M | +0.4% | $3.3B | 0.6% | $447.49 | 45 |
| 2025-Q2 | Increased | 7.2M | +0.5% | $2.3B | 0.5% | $322.83 | 38 |
| 2025-Q1 | Increased | 7.2M | +2.7% | $1.9B | 0.4% | $268.46 | 39 |
| 2024-Q4 | Increased | 7M | +32.9% | $1.6B | 0.3% | $236.01 | 49 |
| 2024-Q3 | Increased | 5.2M | +61.1% | $1.4B | 0.3% | $274.91 | 55 |
| 2024-Q2 | Increased | 3.3M | +3.5% | $791.1M | 0.2% | $243.00 | 39 |